CPHI Online is the largest global marketplace in the pharma ingredients industry

  • Products
    0
  • Companies
    0
  • Articles
    0
  • Events
    0
  • Webinars
    0

HATU chemical reagent

HATU chemical reagent
Product Description

We are specialized in peptide reagents.
Assay: 99% HPLC.

Suzhou Highfine Biotech Co.,Ltd.

  • CN
  • 2015
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Contract Research Organisation (CRO)
Pharmaceutical company
Specifications
  • Details
    We have more than 150 kinds of products. We also do research on and produce more products to meet our customers' need.
    As to other products, please refer to our website or e-mail to us.
  • Supplied from
    China

Suzhou Highfine Biotech Co.,Ltd.

  • CN
  • 2015
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Contract Research Organisation (CRO)
Pharmaceutical company

More Products from Suzhou Highfine Biotech Co.,Ltd. (24)

Frequently Viewed Together

  • Product Shaily Neo - Spring driven pen device

    Spring driven pen injector from Shaily Neo platform
  • Product Solv4U

    Poor water solubility of drug candidates is one of the most common hurdles pharmaceutical development is confronted with. Promising new chemical entities and drug candidates often fail in development due to the limitations of their solubility in water.

    Marinomed Biotech AG provides Solv4U techno...
  • Product FILGRASTIM - NEUTROMAX

    SOLUTION FOR INJECTION. Vials containing filgrastim 300 µg (30 M IU) or 480 µg (48 M IU)
  • Product FERMENTATION SUITE : 50 L, 500 L , 5000 L , 50,000L

    1. In- Situ Fermenters( 5 L – 50,000 L )

    ·         Minimum space requirement

    ·         Agitator(Top/Bottom mounted)

    ·         PLC contro...
  • Product Tergase®

    1. Component:   - Recombinant human hyaluronidase

    2. Indication:   - Tergase® is a stand-alone pharmaceutical version of Recombinant human hyaluronidase which is currently under clinical trial aiming marketing approval in the 3Q of 2022 from MFDS, South Korea. Through the inh...